Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Nasmed Ozelglik Hizmetleri Ticaret AS Debt-to-EBITDA?
Nasmed Ozelglik Hizmetleri Ticaret ASIST:EGEPO +0.61%71 Debt-to-EBITDA is 0.10 as of Jun. 2026, which is 89% below its 10-year median of 0.93. GuruFocus rates IST:EGEPO with a GF Score™ of 71/100 and a GF Value™ of ₺9.38 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 482 Healthcare Providers & Services companies, Nasmed Ozelglik Hizmetleri Ticaret AS ranks better than 89.21% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
IST:EGEPO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.74 Med: 0.93 Max: 4.33
Current: 0.17
During the past 8 years, the highest Debt-to-EBITDA Ratio of Nasmed Ozelglik Hizmetleri Ticaret AS was 4.33. The lowest was -3.74. And the median was 0.93.
IST:EGEPO's Debt-to-EBITDA is ranked better than 89.21% of 482
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs IST:EGEPO: 0.17
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Nasmed Ozelglik Hizmetleri Ticaret AS Debt-to-EBITDA Related Terms
Nasmed Ozelglik Hizmetleri Ticaret AS Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nasmed Ozelglik Hizmetleri Ticaret AS Debt-to-EBITDA Chart
IST:EGEPO vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Nasmed Ozelglik Hizmetleri Ticaret AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nasmed Ozelglik Hizmetleri Ticaret AS Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Nasmed Ozelglik Hizmetleri Ticaret AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nasmed Ozelglik Hizmetleri Ticaret AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Nasmed Ozelglik Hizmetleri Ticaret AS (IST:EGEPO) has a Debt-to-EBITDA of 0.10 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nasmed Ozelglik Hizmetleri Ticaret AS. This is 89% below median its historical median of 0.93. According to the industry distribution chart, Nasmed Ozelglik Hizmetleri Ticaret AS ranks #52 out of 482 companies in the Healthcare Providers & Services industry, placing it in the top 10.8%.
Is Nasmed Ozelglik Hizmetleri Ticaret AS's Debt-to-EBITDA too high?
Nasmed Ozelglik Hizmetleri Ticaret AS's current Debt-to-EBITDA of 0.10 is 89% below median its 10-year median of 0.93. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Nasmed Ozelglik Hizmetleri Ticaret AS's value of 0.10 is 95.4% below this industry median. Based on the distribution chart, Nasmed Ozelglik Hizmetleri Ticaret AS ranks #52 out of 482 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Nasmed Ozelglik Hizmetleri Ticaret AS has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nasmed Ozelglik Hizmetleri Ticaret AS's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Nasmed Ozelglik Hizmetleri Ticaret AS ranks #52 out of 482 companies for Debt-to-EBITDA. This places Nasmed Ozelglik Hizmetleri Ticaret AS in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.19. Nasmed Ozelglik Hizmetleri Ticaret AS's value of 0.10 is 95.4% below this benchmark. While the company's 10-year median is 0.93 vs. the industry median of 2.19, Nasmed Ozelglik Hizmetleri Ticaret AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nasmed Ozelglik Hizmetleri Ticaret AS's current Debt-to-EBITDA of 0.10 is 95.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Nasmed Ozelglik Hizmetleri Ticaret AS. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nasmed Ozelglik Hizmetleri Ticaret AS's current Debt-to-EBITDA is 0.10, which is 89% below median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasmed Ozelglik Hizmetleri Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Nasmed Ozelglik Hizmetleri Ticaret AS (IST:EGEPO) is currently considered Significantly Overvalued. The stock's GF Value™ is ₺9.38, compared to a current price of ₺16.37 — trading 74.5% above its estimated fair value. The current Debt-to-EBITDA is 0.10, which is 89% below median its 10-year median of 0.93 and 95.4% below the Healthcare Providers & Services industry median of 2.19. Nasmed Ozelglik Hizmetleri Ticaret AS's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Nasmed Ozelglik Hizmetleri Ticaret AS (IST:EGEPO), the current Debt-to-EBITDA is 0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nasmed Ozelglik Hizmetleri Ticaret AS (IST:EGEPO) Overvalued in 2026?
Based on GuruFocus' analysis, Nasmed Ozelglik Hizmetleri Ticaret AS stock appears to be overvalued.
The current stock price of ₺16.37 is trading 74.5% above its estimated GF Value™ of ₺9.38.
GuruFocus considers Nasmed Ozelglik Hizmetleri Ticaret AS to be Significantly Overvalued.
Key valuation signals for IST:EGEPO:
Debt-to-EBITDA: 0.10 (89% below median its 10-year median of 0.93)
GF Value™: ₺9.38 vs. price of ₺16.37 (74.5% above fair value)
Industry Position: 95.4% below the Healthcare Providers & Services median (#52 of 482)
No single metric tells the full story. See the IST:EGEPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nasmed Ozel Saglik Hizmetleri Ticaret AS provides quality healthcare services. It arranges consultations, travel planning, accommodation, translation, and other relevant services for its patients 24/7.
71GF Score
Get the complete analysis for IST:EGEPO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:EGEPO has been successfully added to your 
